Sonoma Pharmaceuticals Investor Presentation — November 2018

Document content

SONOMA PHARMACEUTICALS

RESULTS FOR THE QUARTER ENDING 30 September 2018

Welcome / Introduction

September Quarter 2018 Highlights

Jim Schutz / Bob Miller / Marc UmscheidJim Schutz3NASDAQ:

Forward -Looking Statement

Except for historical information herein, matters set forth in this presentation are forward -looking within the

meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including

statements about the commercial and technology progress and future financial performance of Sonoma

Pharmaceuticals, Inc. and its subsidiaries (the “Company”).

These forward -looking statements are identified by the use of words such as “believe,” “achieve,” and

“strive,” among others. Forward -looking statements in this presentation are subject to certain risks and

uncertainties inherent in the Company’s business that could cause actual results to vary, including such risks

that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet

regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be

replicated in actual patient settings, protection offered by the Company’s patents and patent applications may

be challenged, invalidated or circumvented by its competitors, the available market for the Company’s

products will not be as large as expected, the Company’s products will not be able to penetrate one or more

targeted markets, revenues will not be sufficient to fund further development and clinical studies, as well as

uncertainties relative to varying product formulations and a multitude of diverse regulatory and marketing

requirements in different countries and municipalities, and

other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission.

The Company disclaims any obligation to update these forward -looking statements, except as required by law.4NASDAQ:

Results from the Quarter Ending 30 Sep 2018

4Total Revenue = $4.9M

Up 14% versus same period last year

Up 13% versus the quarter ending 30 Jun 2018

Cash as of 30 Sep 2018 = $4M5NASDAQ:

Epicyn Antimicrobial Facial Cleanser -US

New! In January 20196NASDAQ:

Preview truncated — download the full document for the complete content.